Dr. Corinne Maurice-DrorDr Corinne Maurice-Dror

Contact information
Division of Oncology, Rambam Health Care Campus,

8 Ha'aliya St, Haifa, Israel, 35254
Phone: (mobile) 972-52-3990293
E-mail: [email protected]

 

 

 

Academic Degrees
2001-2004           Bachelor of Medical Science, Faculty of Medicine, Hebrew University, Jerusalem, Israel
2005-2008           M.D. degree, Faculty of Medicine, Hebrew University, Jerusalem, Israel

Professional Experience
2019                    Residency Program Director- Oncology Division at the Rambam Health Care Campus, Haifa, Israel.
2019                    Senior physician in Medical Oncology- Oncology Division at the Rambam Health Care Campus, Haifa, Israel.
2015- 2018          Residency in Medical Oncology- Oncology Division at the Rambam Health Care Campus, Haifa, Israel.
2010-2014           Residency in Internal Medicine – Department of Internal Medicine C, Rambam Medical Center, Haifa, Israel
2008-2009           Internship at the Western Galilee hospital in Naharia, Israel.

Work experience
2004-2007           Lab Technician, Blood bank, Clinical Hematology and Biochemistry Lab, Shaare Zedek Medical Center, Jerusalem, Israel
2002-2004           Sleep Medicine Technician, Haddasa Medical Center, Jerusalem, Israel
2000                    Project coordinator, Computer communication systems, NESS, Tel-Aviv, Israel

Teaching Experience
2016-2019           Tutor of 4-6th year medical students on oncology round, Oncology Division, Rambam Health Care Campus, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
1.2016                 Tutor of 3rd year medical students, Introduction to clinical work-Palliative care, Oncology Division, Rambam Health Care Campus, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
2011-2012           Tutor of 4th year medical students, pre-clinical clerkship, Internal Medicine C Department, Rambam Health Care Campus, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
6.2011                 Tutor of 6th year medical students at the internal medicine round, Internal Medicine C Department, RambamHealth Care Campus, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
2004                    Tutor of 2nd year medical students, Medical Physiology, Hebrew University, Jerusalem, Israel.

Clinical Trial experience
2016- To date      Primary investigator, sub investigator and active participant in all Phase 1 and phase 2+3 GU studies- Oncology Division at the Rambam Health Care Campus, Haifa, Israel.
7.2015                 GCP and Clinical Trials Management for Principle Investigators

Publications
Maurice C, Friedman Y, Cohen MJ, Kaliner E, Mimouni M, Kogan M, Blumenthal EZ. Histologic RNFL Thicknes in Glaucomatous Versus Normal Human Eyes. J Glaucoma. 2016 May; 25(5):447-51 Maurice- Dror C, Perets R, Barsela G. Glucocorticoids as an adjunct to oncologic treatment in solid malignancies – Not an innocent bystander. Critical Reviews in Oncology/ Hematology. 126 (2018) 37–44

Maurice-Dror C, Litvak M, Keren-Politansky A ; Ackerman Shanny, Brenner B, Haim N, Nadir ‪Y. In cancer patients using the prophylactic dose of enoxaparin, serum heparan sulfate rates, weight and gender impact anti-Xa levels. Submitted, under review

Abstracts
Maurice-Dror C, Litvak M, Keren A, Akerman S, Brenner B, Hain N, Nadir Y. Is it appropriate to use a fixed dose of enoxaparin for hospitalized cancer patients? Results from prospective tertiary referral center study. ESMO 2018

Awards
2018           Outstanding Resident, Israel Cancer Association, presented during The 17th Annual Meeting of the Israeli Society for Clinical Oncology and Radiation Therapy, January 2018

Grants
2017           Israeli Society of Clinical Oncology and Radiotherapy, ISCORT research grant –
"Microvessel density and complexity as predictive markers for Bevacizumab treatment in metastatic colorectal cancer patients"
2016           Clinical Research Grants for Residents at Rambam Health Care Campus
"Microvessel density and complexity as predictive markers for Bevacizumab treatment in metastatic colorectal cancer patients"

אודות המחבר